Jie Wu, PhD


wie-j

The University of Oklahoma Health Sciences Center
Stanton L. Young Biomedical Research Center
975 NE 10th St, Rm BRC 411B
Oklahoma City, OK 73104

Phone: 405-271-8001, x 31092
E-Mail: jie-wu@ouhsc.edu

Titles

Professor of Pathology
Peggy and Charles Stephenson Endowed Chair in Cancer Translational Research
Co-leader, Cell Signaling and Oncogenes Team, Stephenson Cancer Center
Oklahoma TSET Research Scholar

Education

Xiamen University
Xiamen, China
B.S., 1982

Shanghai Institute of Cell Biology
Chinese Academy of Sciences
Shanghai, China
Graduate Student, 1983

University of Kansas Medical Center
Kansas City, KS
Ph.D., 1988

Memorial Sloan-Kettering Cancer Center
New York, NY
Postdoc, 1990

University of Virginia
Charlottesville, VA
Postdoc, 1994

Research Interests/Sub-Specialty

  • Protein kinases and phosphatases

  • Tumor biology

  • Animal models

  • Cancer genomics

  • Drug discovery and development

  • Sensitivity and resistance to therapy

  • Precision medicine

Publications

  1. Dorsey JF, Cunnick JM, Mane SM, and Wu J. Regulation of the Erk2-Elk1 signaling pathway and megakaryocytic differentiation of the Bcr-Abl+ K562 cells by Gab2. Blood. 2002 Feb; 99(4): 1388-1397.
  2. Ren Y, Chen Z, Chen L, Woods NT, Reuther GW, Cheng JQ, Wang HG, and Wu J. Shp2E76K mutant confers cytokine-independent survival of TF-1 myeloid cells by up-regulating Bcl-XL. J Biol Chem. 2007 Dec; 282(50): 36463-36473.
  3. Ren Y, Zhang Y, Liu RZ, Fenstermacher DA, Wright KL, Teer JK, and Wu J. JAK1 truncating mutations in gynecologic cancer define new role of cancer-associated protein tyrosine kinase aberrations. Sci Rep. 2013 Oct; 3, 3042; doi:10.1038/srep03042.
  4. Schneeberger V, Luetteke N, Ren Y, Berns H, Chen L, Foroutan P, Martinez GV, Haura EB, Chen J, Coppola D, and Wu J. (2014) SHP2E76K mutant promotes lung tumorigenesis in transgenic mice. Carcinogenesis. 2014 Aug; 35(8):1717-25. doi: 10.1093/carcin/bgu025. Epub 2014 Jan 30.
  5. Schneeberger VE, Ren Y, Luetteke N, Huang Q, Chen L, Lawrence HR, Lawrence NJ, Haura EB, Koomen JM, Coppola D, and Wu J. Inhibition of Shp2 suppresses mutant EGFR-induced lung tumors in transgenic mouse model of lung adenocarcinoma. Oncotarget. 2015 Mar; 6(8): 6191-6202.
  6. Fan C, Chen L, Huang Q, Tao S, Welsh EA, Teer JK, Cai J, Cress WD, and Wu J. Overexpression of major CDKN3 transcripts is associated with poor survival in lung adenocarcinoma. Br J Cancer. 2015 Dec; 113(12): 1735-1743.
  7. Huang Q, Schneeberger VE, Luetteke N, Jin C, Afzal R, Budzevich MM, Makanji RJ, Martinez GV, Shen T, Zhao L, Fung KM, Haura EB, Coppola D, and Wu J. Preclinical modeling of KIF5B-RET fusion lung cancer. Mol Cancer Ther. 2016 Oct; 15, 2521-2529.
  8. Shen T, Chen Z, Zhao ZJ, and Wu J. Genetic defects of the IRF1-mediated major histocompatibility complex class I antigen presentation pathway occur prevalently in the JAK2 gene in non-small cell lung cancer. Oncotarget 2017 May; 8 (37): 60975-60986.
  9. Sun X, Ren Y, Gunawan S, Teng P, Chen Z, Lawrence HR, Cai J, Lawrence NJ, and Wu J. Selective inhibition of leukemia-associated SHP2E69K mutant by the allosteric SHP2 inhibitor SHP099. Leukemia 2018 May; 32 (5), 1246-1249.
  10. Liu X, Shen T, Mooers BHM, Hilberg F, Wu J. Drug resistance profiles of mutations in the RET kinase domain. British J. Pharmacol. 2018 Sept; 175, 3504-3515.